An illustration · invented records · this source is real
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)
Kalinsky K, Barlow WE, Pathak HB, Puri RV, et al. (2026). Annals of Oncology. PubMed 42613139 · DOI 10.1016/j.annonc.2026.05.697 · PubMed record
What kind of source: Secondary analysis of RxPONDER, blood hormone markers. Where it sits in the summary: Still being studied. Back to the summary
What it says, in plain language
A 2026 attempt to explain the premenopausal result in RxPONDER: a blood marker of ovarian reserve (AMH) separated premenopausal women who benefited from chemotherapy from those who did not.
Source access: this note uses the published abstract, linked above. The full article was not available for this review and is not included in the folder.
The exact words we relied on
“Among premenopausal patients aged <55 years, participants with baseline AMH <10 pg/ml did not benefit from CET.” — PMID:42613139, Abstract, Conclusion
“Measures of ovarian reserve may refine the selection of patients for CET.” — PMID:42613139, Abstract, Conclusion
How these quotes were checked
Follow the passage links above to the included paper or public source record.
Abstract only. The quotes above come from the paper’s published abstract as held in the PubMed record. They were checked by exact string match against the PubMed record cached on 2026-09-08. This note is limited to the abstract; the full article was not read.
Limits of this source
Applies to premenopausal women under 55. A research finding, not yet a guideline. Abstract only.
Review
Reviewed by Sarah Kiselycznyk · September 10, 2026. Review scope and verification method: How we researched this.